Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

University of California, San Francisco

Division of University of California
www.ucsf.edu

Latest From University of California, San Francisco

Nurix’s $120m Venture Round Will Bring Two Protein-Modulating Therapies To Clinic

Company’s technology harnesses E3 ligases to either degrade dysregulated proteins or inhibit a specific ligase to increase substrate protein levels for therapeutic benefit.

Financing Business Strategies

Tech Transfer Roundup: Be Cool Therapeutics Sees Potential In Mimicking Hibernation

Biotech licenses drug composition patents from University of Alaska Fairbanks for study in several disease states. Gilead seeks long-acting HIV therapy or prevention with broadly neutralizing antibodies discovered by Rockefeller U.

Deals Business Strategies

Venture Funding Deals: Year-End Edition

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced December 2019.

Deals Financing

Finance Watch: Omega, Perceptive/Xontogeny Raise $648m For Life Science Investments

Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.

Financing Innovation
See All
UsernamePublicRestriction

Register